DBV Tech Kickstarts Phase 3 Study Of Modified Viaskin Patch For Peanut Allergy

 

• DBV Technologies SA 
  DBVT+2.73%+ Free Alerts
   initiated Phase 3 study, VITESSE, using the modified Viaskin Peanut Patch in peanut-allergic children ages 4 to 7 years. 
• DBV expects to enroll 600 subjects for participation in the VITESSE study, randomized 2:1 active to placebo. The first patient screened is expected in Q4 2022, with the last patient screened by year-end 2023. 
• The Company anticipates that the topline results will read out in Q1 2025.
• VITESSE is a Phase 3, double-blind, placebo-controlled, randomized study to assess the efficacy and safety of epicutaneous immunotherapy with the modified Viaskin Peanut 250 µg patch in peanut-allergic children ages 4 to 7 years. 
• The primary efficacy endpoint is the percentage of treatment responders in the active versus placebo arms at month 12. 

https://www.benzinga.com/general/biotech/22/09/28796058/dbv-technologies-kickstarts-phase-3-study-of-modified-viaskin-patch-for-kids-with-peanut-allergy